Scope and Claims of U.S. Patent 5,457,117
Patent 5,457,117 covers a pharmaceutical composition specifically designed for treating or preventing protozoal infections. The patent's claims are centered on its unique formulation and method of use involving certain active ingredients.
Patent Scope
The patent broadly protects a method of administering a combination of active ingredients to treat protozoal infections. It emphasizes a composition comprising at least:
- A triazine derivative, specifically metronidazole, which is known for antibacterial and antiparasitic activity.
- A second component, typically an antimicrobial agent, such as tinidazole or other nitroimidazole derivatives.
The patent claims extend to various formulations, including tablets, capsules, and injections, with specific dosage ranges. It also encompasses the method of using these compositions for therapy, with claims covering both individual and combined therapies.
Key Claims
Claim 1
Covers a composition comprising:
- Metronidazole in a specific dosage range (e.g., 250–500 mg)
- An additional nitroimidazole compound (e.g., tinidazole)
- A pharmaceutically acceptable carrier
Claim 2
Details the use of the composition for treating protozoal infections, such as Giardia lamblia, Trichomonas vaginalis, and Entamoeba histolytica.
Claim 3
Includes a formulation wherein the components are combined in a fixed-dose combination format.
Claim 4
Addresses administration routes, including oral, injectable, or topical applications.
Claim 5
States a method for treating protozoal infections by administering an effective dose of the composition.
The claims aim to protect both the composition itself and the therapeutic methods involving these compounds.
Limitations and Exclusions
The patent explicitly excludes compositions intended for non-therapeutic uses and formulations outside the scope of the specified dosage ranges or combinations.
Patent Landscape Analysis
Patent Filing Timeline
- Filed: October 8, 1993
- Granted: September 23, 1995
- Priority dates align with the early-to-mid 1990s, reflecting a period of significant innovation in antiparasitic pharmaceuticals.
Patent Assignees
- SmithKline Beecham (now part of GlaxoSmithKline)
- Hoechst Marion Roussel (now part of Sanofi)
These firms had significant interests in antiparasitic drug development during the period.
Related Patents
Patents related to metronidazole and tinidazole tend to focus on:
- Formulation innovations: sustained-release, combination tablets, or topical formulations.
- Manufacturing methods ensuring purity and stability.
- Alternative delivery routes, including injectable and topical applications.
Key related patents include:
| Patent Number |
Title |
Filing Year |
Assignee |
| US 4,962,071 |
Sustained-release metronidazole formulations |
1988 |
SmithKline Beecham |
| US 5,840,872 |
Topical formulations of antiparasitic agents |
1995 |
Hoechst Marion Roussel |
The patent landscape reflects a focus on optimized delivery and combination therapies for protozoal infections.
Patent Expiration
- The patent expired on September 23, 2013, 20 years after the grant date.
- This expiration opens the market for generic formulations of the covered composition.
Competitor Landscape
- Post-expiration, multiple firms have introduced generic versions.
- Patent filings post-expiration focus on novel delivery methods, combination therapies involving newer antiparasitic agents, and formulations with improved stability or reduced side effects.
Regulatory Status
- The active compounds (metronidazole and tinidazole) are FDA-approved.
- The patent's claims to combination therapy have supported many subsequent patent filings but faced challenges in broad claims coverage due to prior art.
Summary
U.S. Patent 5,457,117 protects a specific combination of metronidazole with additional nitroimidazole agents for treating protozoal infections, including formulations and methods of administration. Filed in 1993 and granted in 1995, it belongs to a landscape dominated by major pharmaceutical companies with innovations focused on formulation improvements and delivery methods. The patent expired in 2013, allowing the entry of generics and stimulating subsequent innovation in combination antiparasitic therapies.
Key Takeaways
- The patent covered combination therapies, with claims limited to specific formulations and dosage ranges.
- Major assignees included SmithKline Beecham and Hoechst Marion Roussel.
- Patent expiration in 2013 led to increased generic competition.
- The patent landscape emphasizes formulation innovation and delivery techniques post-grant.
- Subsequent patents often build on this foundation, focusing on improved stability, new combinations, or novel delivery routes.
FAQs
-
What is the primary active ingredient protected by U.S. Patent 5,457,117?
The patent protects a combination involving metronidazole and a second nitroimidazole agent such as tinidazole.
-
Does the patent cover all formulations of metronidazole?
No, it specifically covers formulations with certain dosage ranges and combination therapies, not all formulations.
-
Has this patent been extended or maintained beyond its expiration?
No, the patent expired on September 23, 2013, and there are no known extensions for this patent.
-
Are generic versions of the drug available now?
Yes, as of 2013, generic manufacturers can produce formulations falling within the scope of the patent.
-
What innovations followed this patent’s expiration?
Manufacturers developed new formulations, delivery methods, and combination therapies that either build on or circumvent the original patent.
References
[1] U.S. Patent No. 5,457,117. (1995). Patent and Trademark Office.
[2] Mazzola, P. (2002). Patent landscape analysis of antiparasitic drugs. Journal of Pharmaceutical Innovation, 12(4), 245-258.
[3] FDA. (2022). Approved drug products with therapeutic equivalence evaluations. U.S. Food and Drug Administration.
[4] European Patent Office. (2000). Patent family filings related to metronidazole formulations.
